Novel approaches in the treatment of multiple myeloma.

Mehrdad Abedi, Gerald J. Elfenbein

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Despite all the new advances, treatment of multiple myeloma remains very challenging. Table 6 summarizes the outcomes of some of the commonly used treatments from different clinical trails. Treatment with conventional chemotherapy alone resulted in median survival from 18 to 30 months. Aggressive treatments like VBMCP (vincristine, bleomycin, melphalan, cyclophosphamide, predisone) although resulting in higher response rates, resulted in higher treatment-related mortality and did not have any effect on median and 5 year survival. High dose chemotherapy with stem cell support increased the median survival to around 60 months and resulted in durable complete responses in a significant number of the patients. Some of the newer and promising treatments for multiple myeloma are summarized in Table 7.

Original languageEnglish (US)
Pages (from-to)231-235
Number of pages5
JournalMedicine and health, Rhode Island
Volume86
Issue number8
StatePublished - 2003
Externally publishedYes

Fingerprint

Multiple Myeloma
Survival
Therapeutics
Drug Therapy
Melphalan
Bleomycin
Vincristine
Cyclophosphamide
Stem Cells
Mortality

Cite this

Novel approaches in the treatment of multiple myeloma. / Abedi, Mehrdad; Elfenbein, Gerald J.

In: Medicine and health, Rhode Island, Vol. 86, No. 8, 2003, p. 231-235.

Research output: Contribution to journalArticle

Abedi, Mehrdad ; Elfenbein, Gerald J. / Novel approaches in the treatment of multiple myeloma. In: Medicine and health, Rhode Island. 2003 ; Vol. 86, No. 8. pp. 231-235.
@article{2456a31d59544b2e83bfe98108c7ceb8,
title = "Novel approaches in the treatment of multiple myeloma.",
abstract = "Despite all the new advances, treatment of multiple myeloma remains very challenging. Table 6 summarizes the outcomes of some of the commonly used treatments from different clinical trails. Treatment with conventional chemotherapy alone resulted in median survival from 18 to 30 months. Aggressive treatments like VBMCP (vincristine, bleomycin, melphalan, cyclophosphamide, predisone) although resulting in higher response rates, resulted in higher treatment-related mortality and did not have any effect on median and 5 year survival. High dose chemotherapy with stem cell support increased the median survival to around 60 months and resulted in durable complete responses in a significant number of the patients. Some of the newer and promising treatments for multiple myeloma are summarized in Table 7.",
author = "Mehrdad Abedi and Elfenbein, {Gerald J.}",
year = "2003",
language = "English (US)",
volume = "86",
pages = "231--235",
journal = "Rhode Island medicine",
issn = "2327-2228",
publisher = "Rhode Island Medical Society",
number = "8",

}

TY - JOUR

T1 - Novel approaches in the treatment of multiple myeloma.

AU - Abedi, Mehrdad

AU - Elfenbein, Gerald J.

PY - 2003

Y1 - 2003

N2 - Despite all the new advances, treatment of multiple myeloma remains very challenging. Table 6 summarizes the outcomes of some of the commonly used treatments from different clinical trails. Treatment with conventional chemotherapy alone resulted in median survival from 18 to 30 months. Aggressive treatments like VBMCP (vincristine, bleomycin, melphalan, cyclophosphamide, predisone) although resulting in higher response rates, resulted in higher treatment-related mortality and did not have any effect on median and 5 year survival. High dose chemotherapy with stem cell support increased the median survival to around 60 months and resulted in durable complete responses in a significant number of the patients. Some of the newer and promising treatments for multiple myeloma are summarized in Table 7.

AB - Despite all the new advances, treatment of multiple myeloma remains very challenging. Table 6 summarizes the outcomes of some of the commonly used treatments from different clinical trails. Treatment with conventional chemotherapy alone resulted in median survival from 18 to 30 months. Aggressive treatments like VBMCP (vincristine, bleomycin, melphalan, cyclophosphamide, predisone) although resulting in higher response rates, resulted in higher treatment-related mortality and did not have any effect on median and 5 year survival. High dose chemotherapy with stem cell support increased the median survival to around 60 months and resulted in durable complete responses in a significant number of the patients. Some of the newer and promising treatments for multiple myeloma are summarized in Table 7.

UR - http://www.scopus.com/inward/record.url?scp=0642367425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0642367425&partnerID=8YFLogxK

M3 - Article

VL - 86

SP - 231

EP - 235

JO - Rhode Island medicine

JF - Rhode Island medicine

SN - 2327-2228

IS - 8

ER -